{
    "clinical_study": {
        "@rank": "92441", 
        "arm_group": [
            {
                "arm_group_label": "Nimotuzumab,docetaxel,capecitabine", 
                "arm_group_type": "Experimental", 
                "description": "Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14"
            }, 
            {
                "arm_group_label": "docetaxel,capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14"
            }
        ], 
        "brief_summary": {
            "textblock": "Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in\n      the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting\n      tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter,\n      phase \u2161 clinical trial of nimotuzumab plus Docetaxel and Capecitabine\uff08TX\uff09versus Docetaxel\n      and Capecitabine\uff08TX\uff09as first-line treatment in patients with recurrent/metastatic triple\n      negative breast cancer."
        }, 
        "brief_title": "Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The control group received docetaxel + capecitabine regimen;Experimental group received\n      Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate\n      Nimotuzumab Plus Docetaxel and Capecitabine\uff08TX\uff09as First-Line Treatment in Patients With\n      Recurrent/Metastatic triple negative breast cancer would improve objective response rate\n      (ORR ) comparing with Docetaxel and Capecitabine\uff08TX\uff09."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic\n             triple-negative breast cancer .\n\n          2. Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy\n             after metastasis.\n\n          3. Females with age between 18 and 70 years old\n\n          4. ECOG performance status 0 or 1.\n\n          5. At least one measurable disease according to the response evaluation criteria in\n             solid tumor (RECIST) by magnetic resonance imaging, or computed tomography; The\n             target lesions is Unresectable; The target lesions did not receive radiotherapy or\n             relapse within the radiation field;\n\n          6. Life expectancy \u2265 12 weeks.\uff1b\n\n          7. WBC count \u2265 4 \u00d7 109 / L, neutrophils \u2265 1.5 \u00d7 109 / L, platelet count \u2265 100 \u00d7 109 / L,\n             hemoglobin \u2265 6.21mmol / L (10 g / dL);\n\n          8. Total bilirubin (TBL)\u2264 1.5 x ULN (upper limit of normal reference values); AST and\n             ALT \u2264 2.5 x ULN or \u2264 5 ULN (Liver metastasis);Serum creatinine \u2264 1.5 x ULN.\n\n          9. Before enrollment, patients have fully recovered from previous treatment-related\n             toxicity;\n\n         10. Subjects with fertility must accept effective contraceptive measures;\n\n         11. Signed informed consent\n\n        Exclusion Criteria:\n\n          1. Previously treatment regimen including anti EGFR monoclonal antibody;\n\n          2. Receiving other anti-cancer medicine treatment during the study\n\n          3. Participate in other clinical trials within 4 weeks in this group;\n\n          4. Accepted taxane treatment in 1 year;\n\n          5. Presence of neurological symptoms due to brain metastasis, patients receiving\n             steroidal anti-edema drugs therapy;\n\n          6. Patients having a history of clinically significant symptomatic angina, arrhythmia or\n             congestive heart failure without control;\n\n          7. Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT;\n\n          8. Pleural effusion, ascites require to be drained;\n\n          9. Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS\n             patients; patients with severe or uncontrolled complications, such as infection\n             requiring systemic therapy, fever (\u2265 38 \u2103), diabetes or hypertension can not be\n             controlled by medicine, other complications may interfere with drug therapy;\n\n         10. Patients with a history of drug allergy (\u2265 CTCAE 2 level) such as shock or allergic\n             symptoms, especially have allergic reactions to similar drugs in the past, have\n             severe allergies reactions to drugs containing polysorbate eighty (Tween 80);\n\n         11. Uncontrolled seizures or loss of insight due to mental disorders;\n\n         12. Pregnant or lactating women\uff1b\n\n         13. Researchers think improper for this trial"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01939054", 
            "org_study_id": "BT-BC-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nimotuzumab,docetaxel,capecitabine", 
                "intervention_name": "Nimotuzumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Nimotuzumab,docetaxel,capecitabine", 
                    "docetaxel,capecitabine"
                ], 
                "intervention_name": "docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Nimotuzumab,docetaxel,capecitabine", 
                    "docetaxel,capecitabine"
                ], 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Docetaxel", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "xubinghe@medmail.com.cn", 
                    "last_name": "Binghe Xu, M.D.", 
                    "phone": "86-10-88788826"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": {
                    "last_name": "Peng Yuan, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "huiping Li"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100142"
                    }, 
                    "name": "Beijing cancer hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "junlan yang"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "The General Hospital of the People's Liberation Army (PLAGH)"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "li cai"
                }, 
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang"
                    }, 
                    "name": "Harbin Medical University Cancer Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "tao sun"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Liaoning Cancer Hospital and Institute"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "xichun Hu"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "FuDan University Shanghai Cancer Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "rui ling"
                }, 
                "facility": {
                    "address": {
                        "city": "Xi-an", 
                        "country": "China", 
                        "state": "Shanxi", 
                        "zip": "710032"
                    }, 
                    "name": "Xijing Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "peifen fu"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "The First Affiliated Hospital of College of Medicine, Zhejiang University (First Hospital of Zhejiang Province)"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "xiaojia wang"
                }, 
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang"
                    }, 
                    "name": "Zhejiang Cancer Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer", 
        "overall_contact": {
            "email": "xubinghe@medmail.com.cn", 
            "last_name": "Binghe Xu", 
            "phone": "86-10-88788826"
        }, 
        "overall_contact_backup": {
            "email": "yuanpeng01@hotmail.com", 
            "last_name": "Peng Yuan", 
            "phone": "86-10-8778 8114"
        }, 
        "overall_official": {
            "affiliation": "Cancer Insititute and Hospital, CAMS", 
            "last_name": "Binghe Xu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation ORR every six weeks,with RECIST 1.1.", 
            "measure": "ORR", 
            "safety_issue": "No", 
            "time_frame": "every six weeks, up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01939054"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese Academy of Medical Sciences", 
            "investigator_full_name": "Binghe Xu", 
            "investigator_title": "Director of Medical Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "every six weeks, up to 1 year"
            }, 
            {
                "description": "Observe and record AEs when AEs occurred", 
                "measure": "Number and ratio of AEs", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "every 6 weeks", 
                "measure": "Relationship of tissue/serum EGFR between efficacy and prognosis", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "source": "Chinese Academy of Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Biotech Pharmaceutical Co., Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}